3,465 research outputs found

    Evaluation of distributed gas cooling of pressurized PAFC for utility power generation

    Get PDF
    A proof-of-concept test for a gas-cooled pressurized phosphoric acid fuel cell is described. After initial feasibility studies in short stacks, two 10 kW stacks are tested. Progress includes: (1) completion of design of the test stations with a recirculating gas cooling loop; (2) atmospheric testing of the baseline stack

    Hybrid PV-Wind, Micro-Grid Development Using Quasi-Z-Source Inverter Modeling and Control—Experimental Investigation

    Get PDF
    This research work deals with the modeling and control of a hybrid photovoltaic (PV)-Wind micro-grid using Quasi Z-source inverter (QZsi). This inverter has major benefits as it provides better buck/boost characteristics, can regulate the phase angle output, has less harmonic contents, does not require the filter and has high power performance characteristics over the conventional inverter. A single ended primary inductance converter (SEPIC) module used as DC-DC switched power apparatus is employed for maximum power point tracking (MPPT) functions which provide high voltage gain throughout the process. Moreover, a modified power ratio variable step (MPRVS) based perturb & observe (P&O) method has been proposed, as part of the PV MPPT action, which forces the operating point close to the maximum power point (MPP). The proposed controller effectively correlates with the hybrid PV, Wind and battery system and provides integration of distributed generation (DG) with loads under varying operating conditions. The proposed standalone micro grid system is applicable specifically in rural places. The dSPACE real-time hardware platform has been employed to test the proposed micro grid system under varying wind speed, solar irradiation, load cutting and removing conditions etc. The experimental results based on a real-time digital platform, under dynamic conditions, justify the performance of a hybrid PV-Wind micro-grid with Quasi Z-Source inverter topology

    Mathematical Modelling of the Relationship between Two Different Temperament Classifications: During the Covid-19 Pandemic

    Get PDF
    In medicine, it is well known that healthy individuals have different physical and mental characteristics. Ancient Indian medicine, Ayurveda and the Persian-Arabic traditional Unani medicine has two distinct approaches for the classification of human subjects according to their temperaments. The individual temperament is an important foundation for personalized medicine, which can help in the prevention and treatment of many diseases including COVID-19. This paper attempts to explore the relationship of the utmost important concepts of these systems called individual temperament named as Prakruti in Ayurveda and Mizaj in Unani practice using mathematical modelling. The results of mathematical modelling can be adopted expediently for the development of algorithms that can be applied in medical informatics. For this, a significant literature review has been carried out. Based on the previous researchers' reviews the essential parameters have been identified for making the relationship and hypothesis were framed. The mathematical modelling was adopted to propose the existence of the relationship between the parameters of such an ancient and rich medicine systems. The hypotheses are validated through the mathematic driven model. Doi: 10.28991/esj-2021-01258 Full Text: PD

    Maximum tolerable dose of cyclophosphamide and azathioprine in Pakistani patients with primary renal disease

    Get PDF
    Objective: The immunosuppressive regimens, at present, mainly rely on western guidelines that were derived from studies conducted in western populations. No such study exists for South Asian population, which is home to almost two billion people different in both genetics and environment from west. Locally derived thresholds for side effects markedly different from western figures may warrant re-adjustment of current local immunosuppressive regimens that are at present based largely on western guidelines. In order to define optimum dose for Cyclophosphamide (CYC) and Azathioprine (AZA) based immunosuppressive therapy, we conducted this study to find out maximum tolerable doses of azathioprine (AZA) and cyclophosphamide (CYC) beyond which neutropenia and thrombocytepenia are most likely to occur in patients with primary renal pathology.METHOD: Patients with systemic vasculitis and idiopathic glomerulonephritis who were on CYC and AZA were identified through review of medical records at a tertiary care hospital in Pakistan (The Aga Khan University Hospital, Karachi). Patients were categorized under three principal diagnosis i.e. systemic lupus erythematosus (SLE), primary (idiopathic) glomerulonephritis (GN) and Wegener\u27s granulomatosis (WG). The Receiver Operating Curve (ROC) was used to calculate the maximum tolerable dose for both CYC and AZA.Results: We identified 94 patients aged 6-82 years (median 44.5 years) with primary renal disease (Wegener\u27s granulomatosis n=13, Systemic lupus erythematosis n=62 and idiopathic glomerulonephritis n=19) who received CYC or AZA. Of these 94 patients, 36.2% (n=34) received CYC and 63.8% (n=60) received AZA. The mean dose of CYC was 1.54 +/- 0.50 mg/kg of body weight (range: 0.77-2.93). The mean dose of AZA was 1.64 +/- 0.59 mg/kg of body weight (range: 0.47-2.97). The maximum tolerable doses calculated for CYC and AZA were 1.25 mg/kg and 1.30 mg/kg of body weight respectively. The maximum tolerable dose for CYC and AZA among males could not be calculated, because of insufficient number of patients who developed neutropenia and thrombocytopenia. The maximum tolerable doses for CYC and AZA among females were 1.34 mg/kg and 1.03 mg/kg of body weight respectively. Also we found out that AZA was relatively more likely to cause neutropenia and thrombocytopenia (p=0.07).CONCLUSION: We thereby recommend that CYC should be initiated at a dose no more than 1 mg/kg of body weight and AZA at an initial dose of 0.75-1.0 mg/kg of body weight. The dose may be adjusted later on the basis of clinical response and laboratory reports
    corecore